OncoLens, an AI/LLM oncology-focused company based in Atlanta, is thrilled to announce Cross Border Impact Venture Fund as its new capital investment partner. Cross Border, a Canada-based impact venture fund, will contribute to OncoLens’ international growth.
OncoLens specializes in providing an integration and collaboration platform for cancer centers. Their platform allows centers to extract valuable insights from various structured and unstructured data sets. These insights empower centers to identify suitable patients for clinical trials, research, biomarker testing, and more. The derived intelligence is then funneled into collaboration workflows and matched with clinical decision support, assisting multi-disciplinary teams in determining the best course of action for their patients.
With the support and partnership of Cross Border, OncoLens plans to expand its reach globally, including into rural communities and low-middle income countries. These regions often lack the necessary capacity, resources, and access to shared expertise to identify the most appropriate diagnostics and treatments for patients. Additionally, OncoLens aims to promote diversity and inclusion in access to healthcare and research.
OncoLens already boasts a network of over 200 cancer centers in the US, with clients in the larger EMEA region (Europe, Middle East, and Africa). This network enables cross collaboration between academic centers, national cancer institutes, community affiliates, large integrated delivery networks, and even across international borders. With the investment from Cross Border, OncoLens looks forward to further facilitating international collaboration, improving patient care, and accessing new revenue opportunities.
Donna Parr, managing director and partner at Cross Border Impact Ventures, expressed excitement about the partnership, stating, With an established network, OncoLens is on the cusp of creating an unprecedented global network of oncology providers that will open up access to cutting edge solutions for patients, enable global collaboration, and intelligence sharing across the oncology ecosystem. We look forward to participating in this journey with the OncoLens team.
OncoLens is dedicated to enabling multidisciplinary cancer care across the continuum. Through their streamlined and secure HIPAA-compliant infrastructure, they drive participation and collaboration among cancer care providers. The platform allows providers to view a comprehensive overview of patients, including clinical data, pathology reports, radiology images, genomics, and genetic information. This holistic approach enables collaborative treatment planning, quality tracking for accreditation, and alignment to care pathways. Ultimately, health systems can maximize clinical trial participation, expand their referral network, and establish centers of excellence for enhanced patient care and provider education.
About Cross Border Impact Ventures:
Cross-Border Impact Ventures is a venture capital firm focused on revolutionizing health technology investing. They invest in early growth stage companies in North America, Europe, and Israel, with an emphasis on technologies relevant to women, children, and adolescent health. Their mission is to expand access to world-class healthcare technologies, breaking down barriers related to gender, age, race, wealth, and borders.
OncoLens and Cross Border’s partnership represents a significant step forward in the global fight against cancer. By leveraging AI and collaboration platforms, OncoLens aims to improve patient outcomes, promote international collaboration, and ensure that cutting-edge solutions are accessible to all. With their shared vision and the support of Cross Border, OncoLens is well-positioned to transform the field of oncology and make a lasting impact on the lives of patients worldwide.
